Table 3

CRS and HIPEC
Author, year Pat. [n] Cytostatic agents (HIPEC) Median OS [mths] Median PFS [mths] OS [%] Survival CC-0/1 [%]
Pilati, 2003 [66] 34 MMC/DDP 18 - 31 (2-y) -
Glehen, 2004 [67] 53 MMC 13 - 32 (2-y) 54 (2-y)
Glehen, 2004 [63] 506 MMC/LOHP 19 - 39 (3-y) 47 (3-y)
Shen, 2004 [68] 77 MMC 16 - 25 (3-y) 44 (3-y)
Verwaal, 03/08 [59,60] 105 MMC 22 12.6 28 (3-y) 45 (5-y)
Quenet, ASCO 08 [69] 37 LOHP/IRI 37 13 - 58 (3-y)
Elias, 2009 [46] 48 LOHP 63 - - 51 (5-y)
Hompes, 2012 [65] 48 LOHP - 19.8 - 89 (2y)

Glockzin et al.

Glockzin et al. BMC Cancer 2013 13:67   doi:10.1186/1471-2407-13-67

Open Data